Data available at inclusion and 5 years (n = 162) | Data available at 1 year and 5 years (n = 161) | |
---|---|---|
Characteristics at inclusion | Characteristics at 1 year | |
Demographics and history | ||
Female sex, n (%) | 114 (70) | 116 (72) |
Age at inclusion (years) | 62 (52–70) | 62 (52–70) |
Symptom duration at inclusion (months) | 7 (5–10) | 7 (5–10) |
Time to first DMARD (months)a | 5 (3–7) | 5 (3–7) |
Current treatment | ||
DMARD (any), n (%) | 138 (85) | 135 (84) |
MTX, n (%) | 85 (52) | 97 (60) |
MTX dose (mg/week) | 10.0 (7.5–10.0) | 10.0 (7.5–15.0) |
Other DMARDs, n (%) | 56 (35) | 51 (32) |
Concurrent prednisolone, n (%) | 60 (37) | 45 (28) |
Prednisolone dose (mg/day) | 7.5 (5.0–15.0) | 5.0 (3.75–7.5) |
Anthropometrics | ||
BMI (kg/m2) | 25 (23–28) | NR |
Obeseb, n (%) | 19 (12) | NR |
Overweightb, n (%) | 69 (45) | NR |
Normal BMIb, n (%) | 66 (43) | NR |
Cigarette smoking status | ||
Current smokers, n (%) | 49 (32) | NR |
Previous smokers, n (%) | 51 (33) | NR |
Never smokers, n (%) | 55 (36) | NR |
Disease parameters | ||
RF-positive at inclusion, n (%) | 105 (65) | 104 (65) |
Anti-CCP antibody-positive at inclusion, n (%) | 83 (59) | 80 (58) |
Modified Sharp–van der Heijde score | 2 (0–8) | 6 (1–16) |
Joint space narrowing score | 0 (0–6) | 4 (0–11) |
Erosion score | 0 (0–2) | 2 (0–4) |
Erosions presentc, n (%) | 28 (17) | 47 (30) |
DAS28 | 4.7 (3.6–5.7) | 3.6 (2.7–4.4) |
Remissiond, n (%) | 12 (8) | 36 (23) |
Low disease activityd, n (%) | 27 (17) | 56 (36) |
Moderate disease activityd, n (%) | 75 (47) | 80 (51) |
High disease activityd, n (%) | 59 (37) | 21 (13) |
HAQ | 0.75 (0.38–1.25) | 0.50 (0.13–0.88) |
Swollen joint count (out of 28) | 7 (5–11) | 4 (2–6) |
Tender joint count (out of 28) | 4 (2–9) | 2 (0–5) |
ESR (mm/h) | 22 (11–43) | 16 (8–30) |
CRP (mg/l)e | 9 (< 9–28) | < 9 (< 9–11) |
Patient’s global assessment (VAS 0–100) | 46 (21–65) | 24 (11–48) |
Pain (VAS 0–100) | 40 (19–61) | 24 (11–44) |